I am not overwhelmed but am encouraged by the news. Seeing stronger effects in patients treated in second period (placebo then DMX-200) vs vice-versa is consistent with a legacy effects in this crossover design (I.e the good effects of DMX-200 taking longer than expected to wash out). The risk-reward profile here, especially given potential REMAP-CAP upside with continued GWAS hits near CCR2, continues to look favorable to me. Of course I would have welcomed partnership news but this is a decent step.
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease, page-4
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
64.5¢ |
Change
0.065(11.2%) |
Mkt cap ! $354.5M | |||
| Open | High | Low | Value | Volume |
| 59.0¢ | 65.0¢ | 58.0¢ | $3.696M | 5.951M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 64.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 65.0¢ | 109360 | 4 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
64.5¢ |
Change
0.065 ( 12.4 %) |
||||
| Open | High | Low | Volume | ||
| 59.0¢ | 65.5¢ | 58.5¢ | 3782284 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| DXB (ASX) Chart |